Dramatic response to single-agent atezolizumab in a patient with MSI-H serous ovarian cancer


Ak N. , Vatansever S.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume:
  • Publication Date: 2021
  • Doi Number: 10.1111/jcpt.13364
  • Title of Journal : JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Abstract

What is known and objective: Patients with ovarian cancer have not benefited substantially from immunotherapy. We report a case of ovarian cancer, however, that responded well to the programmed cell death-ligand 1 inhibitor atezolizumab.